$17.03
0.00%
Nasdaq, Mon, Oct 05 2026.
ISIN
KYG8807B1068
Symbol
TBPH

Theravance Biopharma Inc Target price 2026 - Analyst rating & recommendation

Theravance Biopharma Inc Classifications & Recommendation

Buy
55%
Hold
45%

Theravance Biopharma Inc Price Target

Target Price $17.34
Price $17.03
Potential
Number of Estimates 5
5 Analysts have issued a price target Theravance Biopharma Inc 2027 . The average Theravance Biopharma Inc target price is $17.34. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 6 Analysts recommend Theravance Biopharma Inc to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Theravance Biopharma Inc stock has an average upside potential 2027 of . Most analysts recommend the Theravance Biopharma Inc stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Million $ ??? ???
??? ???
Net Margin ??? ???
??? ???

8 Analysts have issued a sales forecast Theravance Biopharma Inc 2026 . The average Theravance Biopharma Inc sales estimate is

. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .

This results in the following potential growth metrics:

Revenue Estimates

2025 $107m 66.92%
2026
2027
2028
2029
2030
2031
2032
2033

8 Theravance Biopharma Inc Analysts have issued a net profit forecast 2026. The average Theravance Biopharma Inc net profit estimate is

. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $106m 287.70%
2026
2027
2028
2029
2030
2031

Net Margin

2025 98.55% 212.45%
2026
2027
2028
2029
2030
2031

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ ??? ???
??? ???
EV/Sales ???

8 Analysts have issued a Theravance Biopharma Inc forecast for earnings per share. The average Theravance Biopharma Inc EPS is

. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $2.06 277.59%
2026
2027
2028
2029
2030
2031
2032

P/E ratio

Current

Based on analysts' sales estimates for 2026, the Theravance Biopharma Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.07 5.06%
2026
2027
2028
2029
2030
2031
2032
2033

P/S ratio

Current 8.48 9.00%
2026
2027
2028
2029
2030
2031
2032
2033

Current Theravance Biopharma Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
???
Locked
➜
Locked
Locked ???
Analyst Rating Date
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???
Locked
???:
Locked
➜
Locked
???

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today